Biosimilars

COVID-19

Cataract Surgery

Cataract

Cataract Therapeutics

NeuroOp Guru

Clinical Diagnosis

Cornea

Dry Eye Awareness

Dry Eye

Gene Therapy

Geographic Atrophy

IOL Advances

Imaging

Glaucoma Awareness

Glaucoma Insights

Therapeutic Glaucoma

Interventional Glaucoma

Ocular Allergy

Ocular Surface Disease

Optic Relief

Optometry

Pediatrics

Pharmacy

Indispensable

Practice Management

Presbyopia

Ptosis

Refractive Surgery

Refractive

Retina

Surgery

Technology

Therapeutics

Understanding Antibiotic Resistance

Workplace

News

All News

Contributors

Money Matters

Media

All Videos

Expert Interviews

Medical World News

Podcasts

Case Based Roundtable Series

Case of the Quarter

EyeView

Grand Rounds

Insights

Rapid Readout

Viewpoints

What’s Your WhEYE?

Conferences

Conference Coverage

Conference Listing

Events

Publications

Digital Edition

Europe Ophthalmology Times

Modern Retina

Supplements and Featured Publications

Partners

Subscribe

Resources

Job Board

Articles

Insights shed light on what the approval means for providers and their patients affected by this neurodegenerative retinal disease

A new era for MacTel: Clinicians react to FDA approval of revakinagene taroretcel-lwey 

Urcosmid is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor, typically found on immune cells of the eye responsible for the inflammatory response.

OKYO Pharma files application for Fast Track designation with the FDA for urcosimod for the treatment of neuropathic corneal pain

RPESC-RPE-4W is a proprietary retinal pigment epithelium cell therapy for patients with dry age-related macular degeneration.

Luxa Biotechnology presents clinical data from the phase 1/2a trial evaluating RPESC-RPE-4W

4D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) from the retina with a single, safe, intravitreal injection.

4DMT enrolls first patient in phase 3 4FRONT-1 evaluating 4D-150 for the treatment of wet AMD

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.

About

Advertise

Privacy

Editorial Info

Editorial Board

Terms and Conditions

Contact Us

Do Not Sell My Personal Information

Ophthalmology Times - Ophthalmology news, articles, and events

Facebook

Instagram

LinkedIn

Spotlight

Clinical

Glaucoma

View

Advancing Treatment Strategies for Retinal Vascular Diseases with Durable Therapies

Video Series

A case of DME showing significant visual improvement after faricimab therapy  

Videos

Talia R. Kaden, MD​, presents multiple patient cases including a case of choroidal neovascularization with polypoidal choroidal vasculopathy, diabetic macular edema, recurrent retinal vein occlusion, and neovascular age-related macular degeneration with persistent subretinal fluid.

A retina specialist presents an analysis of a case involving polypoidal choroidal vasculopathy. 

A Case of Polypoidal Choroidal Vasculopathy 

An ophthalmologist details a case of diabetic macular edema demonstrating notable visual improvement following treatment with faricimab. 

A Case of DME Showing Significant Visual Improvement After Faricimab Therapy  

An ophthalmologist examines a case of recurrent retinal vein occlusion in a patient with a persistent cyst, exploring the challenges of managing treatment switches. 

A Case of a Multi-Switch RVO Patient With Persistent Cyst 

A retina specialist analyzes a case of neovascular age-related macular degeneration characterized by recurring subretinal fluid. 

A Case of Neovascular AMD With Recurrent Subretinal Fluid 

A Case of DME Showing Significant Visual Improvement After Faricimab Therapy

EP: 1.A Case of Polypoidal Choroidal Vasculopathy

EP: 2.A Case of DME Showing Significant Visual Improvement After Faricimab Therapy

EP: 3.A Case of a Multi-Switch RVO Patient With Persistent Cyst

EP: 4.A Case of Neovascular AMD With Recurrent Subretinal Fluid